Established Versus Novel Strategies for Hepatitis B Functional Cure: A Cross-Regional Cost-Effectiveness Analysis of Pegylated Interferon and Bepirovirsen Add-on Therapy
Publication date: January–February 2027 Source: Journal of Clinical and Experimental Hepatology, Volume 17, Issue 1 Author(s): Jing Chen, Shi Zhao, Jidong Jia, Hong You, Dong Ji, Ji M. Yang, Tawesak Tanwandee, Diana Payawal, Jia-Hong Kao, Saeed Hamid, Jian Sun, Hui Wang, Young S. Lim, Masao Omata, George Lau
Established Versus Novel Strategies for Hepatitis B Functional Cure: A Cross-Regional Cost-Effectiveness Analysis of Pegylated Interferon and Bepirovirsen Add-on Therapy. // Journal of Clinical and Experimental Hepatology. – URL: https://www.sciencedirect.com/science/article/pii/S0973688326002197?dgcid=rss_sd_all
Established Versus Novel Strategies for Hepatitis B Functional Cure: A Cross-Regional Cost-Effectiveness Analysis of Pegylated Interferon and Bepirovirsen Add-on Therapy. Journal of Clinical and Experimental Hepatology. https://www.sciencedirect.com/science/article/pii/S0973688326002197?dgcid=rss_sd_all
“Established Versus Novel Strategies for Hepatitis B Functional Cure: A Cross-Regional Cost-Effectiveness Analysis of Pegylated Interferon and Bepirovirsen Add-on Therapy.” Journal of Clinical and Experimental Hepatology.
@article{article52473,
title = {Established Versus Novel Strategies for Hepatitis B Functional Cure: A Cross-Regional Cost-Effectiveness Analysis of Pegylated Interferon and Bepirovirsen Add-on Therapy},
journal = {Journal of Clinical and Experimental Hepatology},
url = {https://www.sciencedirect.com/science/article/pii/S0973688326002197?dgcid=rss_sd_all}
}